Search Results

Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced the availability of the first paper produced by a research collaboration with Lawrence Berkeley National Laboratory (LBNL) and Los Alamos National Laboratory (LANL) and funded by the U.S. Department of Energy and the Defense Threat Reduction Agency (DTRA), which addresses the clear and critical need for pathogen agnostic diagnostics that can be quickly and effectively performed at point of need.

Cingulate Inc. announced that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin.

DNA Nanobots, a biotechnology leader in DNA nanoparticles engineered for targeted therapeutics, announced that it completed exclusive commercial licensing of a gene editing technology from the University of California Berkeley.

CooperCompanies announced that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023.

The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.

NYU Grossman School of Medicine’s Vilcek Institute of Graduate Biomedical Sciences and Sarah Lawrence College announced the launch of a master’s program in genome health analysis.

Rafa Laboratories, LTD., a leading manufacturer of Emergency Medical Solutions, and the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, aim to enhance the national preparedness for nerve agent emergencies by developing a new design for Rafa’s pediatric atropine autoinjectors.

bioLytical Laboratories Inc. proudly announces its donation of 1,200 INSTI® HIV-1/2 Antibody Tests to KFF’s Greater Than AIDS campaign in support of National HIV Testing Day, June 27.

ARUP Laboratories today released the company’s public comment on the FDA’s proposed rule to regulate laboratory-developed tests (LDTs) as medical devices, urging the agency to withdraw the rule.